Several studies have demonstrated that the Tat-p27 fusion protein is efficiently delivered to cardiomyocytes, and treatment with Tat-p27 protects cardiomyocytes from myocardial infarction [17,18]. This evidence concerns the gene CDKN1B and myocardial infarction.